BUY Dr. Lal Path Labs Ltd. — Arun Kumar Mantri
byArun Kumar MantriHorizon: Intraday25 Sept 2026, 9:31 am ISTvia CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Dr. Lal Path Labs Ltd. approved the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. SN Genelab will become a subsidiary.
NSE · Outcome of Board Meeting·24 Sept · today
Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. This acquisition aims to strengt
BSE · Company Update·24 Sept · today
Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance-linked earn out. SN Genelab will become a subsidi
BSE · Others·24 Sept · today
1 advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · adjacent horizon·25 Sept · today
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Dr. Lal Path Labs
- BUY — Amit Seth9 Nov 2026 · Same day · target ₹2,120 · Expired
- BUY — Sudeep Shah, SBICAP Securities9 Nov 2026 · ~2 weeks · target ₹2,150 · Active
- BUY — Shrikant Chouhan, Kotak Securities5 Nov 2026 · ~2 weeks · target ₹2,150 · SL hit
- SELL — Citigroup5 Nov 2026 · ~1 year · target ₹1,750 · Active
- BUY — Citigroup5 Nov 2026 · ~1 year · target ₹2,380 · Active
More from Arun Kumar Mantri
- BUY ACME Solar Holdings13 Nov 2026 · ~2 weeks · target ₹438 · SL hit
- BUY Cipla13 Nov 2026 · Same day · target ₹1,450 · Expired
- BUY Laurus Labs13 Nov 2026 · Same day · target ₹2,468 · Expired
- BUY Mankind Pharma13 Nov 2026 · Same day · target ₹2,710 · Expired
- BUY Oberoi Realty13 Nov 2026 · Same day · target ₹1,863 · SL hit

